PDCD1 and head and neck squamous cell carcinoma: Other ongoing clinical trials include the IT TLR-7 agonist LHC165 in combination with anti-PD-1 in patients with advanced solid tumours (NCT03301896), the TLR-8 agonist motolimod in combination with anti-PD-1 agent nivolumab in HNSCC (Phase 1, NCT03906526) and BCG in combination with Durvalumab +/- RT in NMIBC (NCT03317158).